Crititech, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Michael Baltezor

Juan Jose Marugan

Noel Terrence Southall

Matthew McClorey

Joseph S Farthing

Mark D Williams

Gere S diZerega

Charles J Decedue

Sam Campbell

Marc Ferrer

Jahna Espinosa

Samarjit Patnaik

Sui Huang

Jake Sittenauer

Samuel Campbell

Julia K Fischer

Jacob M Sittenauer

Gary E Clapp

Holly Maulhardt

Shelby Clark

Gere Dizerega

William Johnston

James Verco

Marc Iacobucci

Aranza Barreda Abarca

John Haslam

Christopher R Dextras

Udo Rudloff

Serguei Kozlov

John C Braisted

Matthew Mcclorey

Garry E Clapp

Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, and intracystic injection.

Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer

Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.

Treatment of epithelial cysts by intracystic injection of antineoplastic particles

The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.

Lapatinib particles and uses thereof

Disclosed herein are particles of at least 95% by weight of a glucocorticoid that have a specific surface area of at least 10 mmethods for making, such particles, and methods for their use as therapeutics. Also disclosed herein are particles of at least 95% by weight of an indolinone that have a specific surface area of at least 10 m/g, methods for making such particles, and methods for-their use as therapeutics.

Glucocorticoid 'nintedanib' particles and their use

Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, arid intracystic injection.

Compositions of particles having at least 95% by weight of niraparib and a specific surface area (SSA) of at least 5 m/g, methods for their use, and methods for their production are provided.

Niraparib particles and uses thereof

Compositions of particles having at least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m/g, methods for their use, and methods for their production are provided.

Rucaparib particles and uses thereof

Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.

Methods for treating lung disorders

Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cmand about 0.15 g/cm, and/or a specific surface area (SSA) of at least 18 m/g, 20 m/g, 25 m/g, 30 m/g, 32 m/g, 34 m/g, or 35 m/g. Methods for making and using such compositions are also provided.

Taxane particles and their use

The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.

Ciprofloxacin polymorph and its use

Growing community of inventors

Lawrence, KS, United States of America

Michael Baltezor